Loading
Led trials that brought immunotherapy into bladder cancer and tested skipping cystectomy in responders.
Matthew D. Galsky is Director of Genitourinary Medical Oncology and Co-Director of the Center of Excellence for Bladder Cancer at The Mount Sinai Hospital and Tisch Cancer Institute. He is a genitourinary oncologist known for leading trials that brought immunotherapy into bladder cancer, including IMvigor130, and for testing whether responders to chemo-immunotherapy can skip cystectomy. His selected paper reports atezolizumab with or without chemotherapy in metastatic urothelial cancer in IMvigor130. He continues to study bladder preservation in muscle-invasive disease and immunotherapy with atezolizumab and nivolumab.
| Title | Journal | Year |
|---|---|---|
| Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130) | Lancet | 2020 |
| NIAGARA: durvalumab before and after cystectomy for muscle-invasive bladder cancer | New England Journal of Medicine | 2024 |
Shares Atezolizumab, PD-L1, Bladder & urothelial cancer.
Shares Atezolizumab, PD-L1, Bladder & urothelial cancer.
Shares Atezolizumab, Nivolumab.
Shares Atezolizumab, Nivolumab, Bladder & urothelial cancer.
Shares NIAGARA: durvalumab before and after cystectomy for muscle-invasive bladder cancer, Atezolizumab, PD-L1, Bladder & urothelial cancer.
Shares Atezolizumab, Bladder & urothelial cancer.
Shares PD-L1, Bladder & urothelial cancer.
Shares Atezolizumab, PD-L1, Bladder & urothelial cancer.